Literature DB >> 30466686

Biologics and Psoriasis: The Beat Goes On.

Hee J Kim1, Mark G Lebwohl2.   

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biologics; Efficacy; Psoriasis; Psoriatic arthritis; Safety; Th17/IL-23 axis

Mesh:

Substances:

Year:  2018        PMID: 30466686     DOI: 10.1016/j.det.2018.07.004

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  11 in total

Review 1.  Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection.

Authors:  Courtney E Heron; Rima I Ghamrawi; Esther A Balogh; Steven R Feldman
Journal:  Am J Clin Dermatol       Date:  2020-11-09       Impact factor: 7.403

Review 2.  Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis.

Authors:  Tse-Hung Huang; Chwan-Fwu Lin; Ahmed Alalaiwe; Shih-Chun Yang; Jia-You Fang
Journal:  Int J Mol Sci       Date:  2019-05-24       Impact factor: 6.208

3.  Eczematous eruption after guselkumab treatment for psoriasis.

Authors:  Birgit Reyn; Tom Hillary; Ann Gils
Journal:  JAAD Case Rep       Date:  2019-10-24

4.  The endoribonuclease N4BP1 prevents psoriasis by controlling both keratinocytes proliferation and neutrophil infiltration.

Authors:  Chenliang Gou; Wenkai Ni; Panpan Ma; Fengbo Zhao; Zhou Wang; Rong Sun; Yingcheng Wu; Yuanyuan Wu; Miaomiao Chen; Hao Chen; Jie Zhang; Yu Shen; Mingbing Xiao; Cuihua Lu; Renfang Mao; Yihui Fan
Journal:  Cell Death Dis       Date:  2021-05-14       Impact factor: 8.469

5.  A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis.

Authors:  Krzysztof Bojanowski; Collins U Ibeji; Parvesh Singh; William R Swindell; Ratan K Chaudhuri
Journal:  JID Innov       Date:  2021-07-08

6.  Risk for Hepatitis B Virus Reactivation in Patients with Psoriasis Treated with Biological Agents: A Systematic Review and Meta-Analysis.

Authors:  Xinyu Wang; Ming Zhang; Yu Chen; Yirong Liu; Yan Yu; Xiaojie Huang; Yanqing Gao
Journal:  Dermatol Ther (Heidelb)       Date:  2022-01-29

7.  Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis.

Authors:  Christos Prevezas; Alexander C Katoulis; Evangelia Papadavid; Pantelis Panagakis; Dimitrios Rigopoulos
Journal:  Skin Appendage Disord       Date:  2019-05-21

Review 8.  From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.

Authors:  Silvia Vidal; Lluís Puig; José-Manuel Carrascosa-Carrillo; Álvaro González-Cantero; José-Carlos Ruiz-Carrascosa; Antonio-Manuel Velasco-Pastor
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

9.  A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.

Authors:  A Blauvelt; K Papp; A Gottlieb; A Jarell; K Reich; C Maari; K B Gordon; L K Ferris; R G Langley; Y Tada; R G Lima; H Elmaraghy; G Gallo; L Renda; S Y Park; R Burge; J Bagel
Journal:  Br J Dermatol       Date:  2020-01-15       Impact factor: 9.302

Review 10.  Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.

Authors:  Andrea Luengas-Martinez; Ralf Paus; Helen S Young
Journal:  Br J Dermatol       Date:  2022-03-17       Impact factor: 11.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.